Reduction in Tcf7l2 expression decreases diabetic susceptibility in mice

International Journal of Biological Sciences

Volumn 8, Issue 6, 2012, Pages 791-801

  Yang, Hyekyung ^a   Li, Qing ^a   Lee, Jong Hwan ^b   Shu, Yan ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b Konkuk University   (South Korea)

Author keywords

Diabetes; Gluconeogenesis; Glucose tolerance; Hepatic steatosis; High fat diet; Tcf7l2

Indexed keywords

TRANSCRIPTION FACTOR 7 LIKE 2;

ANIMAL; ARTICLE; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DIABETES MELLITUS; GENETICS; GLUCOSE BLOOD LEVEL; LIPID DIET; MALE; METABOLISM; MOUSE; MOUSE MUTANT; PANCREAS ISLET;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS; DIET, HIGH-FAT; ISLETS OF LANGERHANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; TRANSCRIPTION FACTOR 7-LIKE 2 PROTEIN;

MUS;

EID: 84863753084     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.4568     Document Type: Article

References (41)

1. Jin T. The WNT signaling pathway and diabetes mellitus. Diabetologia 2008; 51: 1771-1780.
2. Christodoulides C, Lagathu C, Sethi JK, Vidal-Puig A. Adipogenesis and WNT signaling. Trends Endocrinol Metab 2009; 20: 16-24.
3. Heller RS, Dichmann DS, Jensen J, Miller C, Wong G, Madsen OD et al. Expression patterns of Wnts, Frizzleds, sFRPs, and misexpression in transgenic mice suggesting a role for Wnts in pancreas and foregut pat-tern formation. Dev Dyn 2002; 225: 260-270.
4. Welters HJ, Kulkarni RN. Wnt signaling: relevance to β-cell biology and diabetes. Trends Endocrinol Metab 2009; 19: 349-355.
5. Angus-Hill ML, Elbert KM, Hidalgo J, Capecchi MR. T-cell factor 4 functions as a tumor suppressor whose disruption modulates colon cell proliferation and tumorigenesis. Proc Natl Acad Sci U S A 2011; 108: 4914-4919.
6. Liu H, Fergusson MM, Wu JJ, Rovira II, Liu J, Gavrilova O et al. Wnt signaling regulates hepatic metabolism. Sci Signal 2011; 4: ra6
7. Kanazawa A, Tsukada S, Sekine A, Tsunoda T, Takahashi A, Kashiwagi A et al. Association of the gene encoding wingless-type mammary tumor virus integration-site family member 5B (WNT5B) with type 2 diabetes. Am J Hum Genet 2004; 75: 832-843.
8. Christodoulides C, Scarda A, Granzotto M, Milan G, Dalla Nora E, Keogh J et al. WNT10B mutations in human obesity. Diabetologia 2006; 49: 678-684.
9. Mani A, Radhakrishnan J, Wang H, Mani A, Mani MA, Nelson-Williams C et al. LRP6 mutation in a family with early coronary disease and met-abolic risk factors. Science 2007; 315: 1278-1282.
10. Salpea KD, Gable DR, Cooper JA, Stephens JW, Hurel SJ, Ireland HA et al. The effect of WNT5B IVS3C>G on the susceptibility to type 2 diabetes in UK Caucasian subjects. Nutr Metab Cardiovasc Dis 2009; 19: 140-145.
11. Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006; 8: 320-323.
12. Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PI, Shuldiner AR et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Eng J Med 2006; 355: 241-250.
13. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL et al. A genome-wide association study of type 2 diabetes in Finns detects mul-tiple susceptibility variants. Science 2007; 316: 1341-1345.
14. Bonetti S, Trombetta M, Malerba G, Boselli L, Trabetti E, Muggeo M et al. Variants and haplotypes of TCF7L2 are associated with β-cell function in patients with newly diagnosed type 2 diabetes: the Verona Newly Di-agnosed Type 2 Diabetes Study (VNDS) 1. J Clin Endocrinol Metab 2011; 96: E389-E393.
15. Strawbridge RJ, Dupuis J, Prokopenko I, Barker A, Ahlqvist E, Rybin D et al. Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the path-ophysiology of type 2 diabetes. Diabetes 2011; 60: 2624-2634.
16. Lyssenko V, Lupi R, Marchetti P, Del Guerra S, Orho-Melander M, Almgren P et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 2007; 117: 2155-2163.
17. Elbein SC, Chu WS, Das SK, Yao-Borengasser A, Hasstedt SJ, Wang H et al. Transcription factor 7-like 2 polymorphisms and type 2 diabetes, glucose homeostasis traits and gene expression in US participants of European and African descent. Diabetologia 2007; 50: 1621-1630.
18. Lee SH, Demeterco C, Geron I, Abrahamsson A, Levine F, Itkin-Ansari P. Islet specific Wnt activation in human type II diabetes. Exp Diabetes Res 2008; 2008: 728763.
19. Shu L, Sauter NS, Schulthess FT, Matveyenko AV, Oberholzer J, Maedler K. Transcription factor 7-like 2 regulates beta-cell survival and function in human pancreatic islets. Diabetes 2008; 57: 645-653.
20. Shu L, Matveyenko AV, Kerr-Conte J, Cho JH, McIntosh CH, Maedler K. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP-and GLP-1 receptors and impaired be-ta-cell function. Hum Mol Genet 2009; 18: 2388-2399.
21. El Muayed M, Billings LK, Raja MR, Zhang X, Park PJ, Newman MV et al. Acute cytokine-mediated downregulation of the zinc transporter ZnT8 alters pancreatic beta-cell function. J Endocrinol 2010; 206: 159-169.
22. Lillie RD, Ashburn LL. Supersaturated solutions of fat stains in dilute isopropanol for demonstration of acute fatty degeneration not shown by Herxheimer's technique. Arch Pathol 1943; 36: 432-440.
23. Testa G, Schaft J, van der Hoeven F, Glaser S, Anastassiadis K, Zhang Y et al. A reliable lacZ expression reporter cassette for multipurpose, knockout-first alleles. Genesis 2004; 38: 151-158.
24. Korinek V, Barker N, Moerer P, van Donselaar E, Huls G, Peters PJ et al. Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat Genet 1998; 19: 379-383.
25. Savic D, Ye H, Aneas I, Park SY, Bell GI, Nobrega MA. Alterations in TCF7L2 expression define its role as a key regulator of glucose metabo-lism. Genome Res 2011; 21: 1417-1425.
26. Wahren J, Ekberg K. Splanchnic regulation of glucose production. Annu Rev Nutr 2007; 27: 329-345.
27. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-887.
28. Lee JM, Lee YK, Mamrosh JL, Busby SA, Griffin PR, Pathak MC et al. A nuclear-receptor-dependent phosphatidylcholine pathway with antidi-abetic effects. Nature 2011; 474: 506-510.
29. Rijzewijk LJ, van der Meer RW, Lubberink M, Lamb HJ, Romijn JA, de Roos A et al. Liver fat content in type 2 diabetes: Relationship with he-patic perfusion and substrate metabolism. Diabetes 2010; 59: 2747-2754.
30. Seppälä-Lindroos A, Vehkavaara S, Häkkinen AM, Goto T, Westerbacka J, Sovijärvi A et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002; 87: 3023-3028
31. Kotronen A, Vehkavaara S, Seppälä-Lindroos A, Bergholm R, Yki-Järvinen H. Effect of liver fat on insulin clearance. Am J Physiol En-docrinol Metab 2007; 293: E1709-E1715.
32. Haramizu S, Nagasawa A, Ota N, Hase T, Tokimitsu I, Murase T. Dif-ferent contribution of muscle and liver lipid metabolism to endurance capacity and obesity susceptibility of mice. J Appl Physiol 2009; 106: 871-879.
33. Gaulton KJ, Nammo T, Pasquali L, Simon JM, Giresi PG, Fogarty MP et al. A map of open chromatin in human pancreatic islets. Nat Genet 2010; 42: 255-259.
34. Stitzel ML, Sethupathy P, Pearson DS, Chines PS, Song L, Erdos MR et al. Global epigenomic analysis of primary human pancreatic islets provides insights into type 2 diabetes susceptibility loci. Cell Metab 2010; 12: 443-455.
35. Hindle AK, Brody F, Tevar R, Kluk B, Hill S, McCaffrey T et al. TCF7L2 expression in diabetic patients undergoing bariatric surgery. Surg Endosc 2009; 23: 700-704.
36. Prokunina-Olsson L, Welch C, Hansson O, Adhikari N, Scott LJ, Usher N et al. Tissue-specific alternative splicing of TCF7L2. Hum Mol Genet 2009; 18: 3795-3804.
37. Weise A, Bruser K, Elfert S, Wallmen B, Wittel Y, Wöhrle S et al. Alter-native splicing of Tcf7l2 transcripts generates protein variants with dif-ferential promoter-binding and transcriptional activation properties at Wnt/beta-catenin targets. Nucleic Acids Res 2010; 38: 1964-1981.
38. Mondal AK, Das SK, Baldini G, Chu WS, Sharma NK, Hackney OG et al. Genotype and tissue-specific effects on alternative splicing of the tran-scription factor 7-like 2 gene in humans. J Clin Endocrinol Metab 2010; 95: 1450-1457.
39. Le Bacquer O, Shu L, Marchand M, Neve B, Paroni F, Kerr Conte J et al. TCF7L2 splice variants have distinct effects on beta-cell turnover and function. Hum Mol Genet 2011; 20: 1906-1915.
40. Moldeus P, Hogberg J, Orrenius S. Isolation and use of liver cells. Meth-ods Enzymol 1978; 52: 60-71.
41. Roose J, Clevers H. TCF transcription factors: molecular switches in carcinogenesis. Biochim Biophys Acta 1999; 1424: M23-37.